| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Aarti Drugs Limited (NSE: AARTIDRUGS)
AARTIDRUGS Technical Analysis
1.5
| As on 25th Apr 2024 AARTIDRUGS SHARE Price closed @ 500.20 and we RECOMMEND Sell for LONG-TERM with Stoploss of 506.96 & Buy for SHORT-TERM with Stoploss of 494.25 we also expect STOCK to react on Following IMPORTANT LEVELS. |
AARTIDRUGSSHARE Price
| Open | 499.00 | Change | Price | % |
| High | 504.30 | 1 Day | -0.55 | -0.11 |
| Low | 498.55 | 1 Week | 7.85 | 1.59 |
| Close | 500.20 | 1 Month | 44.60 | 9.79 |
| Volume | 68793 | 1 Year | 79.35 | 18.85 |
| 52 Week High 617.60 | 52 Week Low 317.10 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.90 | 6.11% |
| YESBANK | 25.95 | 1.96% |
| KOTAKBANK | 1642.45 | -10.87% |
| SOUTHBANK | 30.40 | 4.47% |
| SAIL | 164.95 | 0.18% |
| PNB | 135.90 | 2.18% |
| TATASTEEL | 167.70 | 1.30% |
| AXISBANK | 1127.00 | 6.00% |
| IRFC | 150.25 | 0.84% |
| IOB | 66.90 | 5.77% |
NSE INDIA Top Gainers Stocks
| ROML | 75.65 | 19.98% |
| POWERINDIA | 9329.50 | 13.60% |
| GPTINFRA | 211.80 | 12.51% |
| NEOGEN | 1557.75 | 12.25% |
| PNC | 65.00 | 11.02% |
| PNC | 65.00 | 11.02% |
| PNC | 65.00 | 11.02% |
| PNC | 65.00 | 11.02% |
| MOIL | 430.70 | 10.88% |
| GODFRYPHLP | 3449.70 | 10.17% |
NSE INDIA Top Losers Stocks
| AARTIDRUGS Daily Charts |
AARTIDRUGS Intraday Charts |
Whats New @ Bazaartrend |
AARTIDRUGS Free Analysis |
|
|
AARTIDRUGS Important Levels Intraday
| RESISTANCE | 511.28 |
| RESISTANCE | 507.73 |
| RESISTANCE | 505.53 |
| RESISTANCE | 503.33 |
| SUPPORT | 497.07 |
| SUPPORT | 494.87 |
| SUPPORT | 492.67 |
| SUPPORT | 489.12 |
AARTIDRUGS Target April 2024
| 4th UP Target | 656.96 |
| 3rd UP Target | 607.52 |
| 2nd UP Target | 576.96 |
| 1st UP Target | 546.4 |
| 1st DOWN Target | 459.2 |
| 2nd DOWN Target | 428.64 |
| 3rd DOWN Target | 398.08 |
| 4th DOWN Target | 348.64 |
AARTIDRUGS Weekly Target
| 4th UP Target | 563.70 |
| 3rd UP Target | 541.67 |
| 2nd UP Target | 528.05 |
| 1st UP Target | 514.43 |
| 1st DOWN Target | 475.57 |
| 2nd DOWN Target | 461.95 |
| 3rd DOWN Target | 448.33 |
| 4th DOWN Target | 426.30 |
AARTIDRUGS Target2024
| 4th UP Target | 1128.67 |
| 3rd UP Target | 923.59 |
| 2nd UP Target | 796.82 |
| 1st UP Target | 670.06 |
| 1st DOWN Target | 308.34 |
| 2nd DOWN Target | 181.58 |
| 3rd DOWN Target | 54.81 |
| 4th DOWN Target | -150.27 |
Aarti Drugs Limited ( NSE INDIA Symbol : AARTIDRUGS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
AARTIDRUGS Synopsis Technicals View
| 50 Day EMA |
Close is Below EMA 50 (Short Term) |
Bearish | |
| 100 Day EMA | Close is Below EMA 100 (Mid Term) | Bearish | |
| 200 Day EMA | Close is Below EMA 200 (Long Term) | Bearish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is 57.27 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Short Sell | 591.43 | |
| 10 Day Avg Volume | Traded -36.18 % Less then 10 Day Average Volume | ||
AARTIDRUGS Other Details
| Segment | EQ | |
| Market Capital | 57860685824.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
AARTIDRUGS Address
 |
||
AARTIDRUGS Latest News
AARTIDRUGS Business Profile
Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide, sodium salt, benzyl nicotinate, bisphenol ? C, bisphenol ? C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Additionally, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India. Address: Mahendra Industrial Estate, Mumbai, India, 400 022
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service